Purchase Order 75N92020P00220

The National Institutes of Health's National Human Genome Research Institute awarded a $20,000 firm fixed price purchase order to Alstem, Inc. of San Pablo, California. Under the terms of the contract, Alstem will provide induced pluripotent stem cell generation from human fibroblasts using an episomal method. The work will be conducted at Alstem's place of performance in San Pablo and will be completed by December 31, 2023. No major subcontractors or set aside designations were identified....

This is a firm fixed price purchase order contract awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Human Genome Research Institute to Alstem, Inc., a minority-owned, for-profit small business, for $49,800.00. The contract is for services to generate human induced pluripotent stem (iPS) cells using episomal vector technology, in support of the agency's stem cell research and development efforts. Alstem, which specializes in induced...

This federal contract award from the National Human Genome Research Institute, an agency within the U.S. Department of Health and Human Services, was made to the New York Stem Cell Foundation Inc., a non-profit organization that conducts stem cell research. The contract, valued at $425,000.00, is for the generation of 50 induced pluripotent stem cell (iPSC) lines from fusion study fibroblast cell lines. No set-aside designation was used for this contract. The New York Stem Cell Foundation Inc....

This contract was awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Institute on Drug Abuse to Applied Stemcell, Inc., a minority-owned, woman-owned small business, for a firm-fixed-price purchase order in the amount of $63,000.00. The contract calls for the use of CRISPR gene editing technology to create two custom induced pluripotent stem cell (iPSC) reporter cell lines - one with dual gene knock-ins for albumin and alpha-fetoprotein, and...

This purchase order awards Fujifilm Cellular Dynamics, Inc. $349,700 for induced pluripotent stem (iPS) cell-derived differentiated cells to support the National Center for Advancing Translational Sciences within the National Institutes of Health's National Institute on Drug Abuse. The contract delivers over 300 units of various iPS cell-derived differentiated cells to develop three-dimensional tissue models of the brain. A pre-solicitation notice sought capability statements for a potential...

The U.S. Food and Drug Administration (FDA), through its National Center for Toxicological Research (NCTR), awarded a $24,895.00 firm-fixed-price purchase order to Fujifilm Cellular Dynamics, Inc. for the supply of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes (hiPSC-CMs), also referred to as "iCell Macrophages" from lot #106775. This sole-source procurement was conducted under the authority of FAR 13.106-1(b)(1) to support an approved scientific study (S00913) focused...

This is a $50,000.00 firm fixed-price purchase order awarded by the U.S. Environmental Protection Agency's Office of Research and Development to Fujifilm Cellular Dynamics, Inc., a foreign-owned, for-profit manufacturer of induced pluripotent stem cell-derived human cell products. The contract is for the provision of laboratory supplies and reagents, specifically a range of specialized cell types such as cardiomyocytes, neurons, astrocytes, hepatocytes, and endothelial cells. These cell products...

The Department of Health and Human Services National Institutes of Health National Center for Advancing Translational Sciences awarded a $287,502 firm fixed price purchase order to Fujifilm Cellular Dynamics, Inc. to provide induced pluripotent stem cell-derived neuronal and endothelial cells. The solicitation sought these cell types on a non-competitive basis from the incumbent contractor to maintain consistent data for ongoing biofabrication of three-dimensional tissue models in the Stem...

This is a $24,900 firm-fixed-price purchase order awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Center for Advancing Translational Sciences to 3Dnamics Inc., a biotechnology company that provides stem cell engineering technology and related services. The contract is for the differentiation of induced pluripotent stem cells (iPSCs) into hepatocyte organoids, which are three-dimensional cell cultures that model liver tissue. This work supports...

This is a $13,760 firm fixed price purchase order awarded by the National Institute of Child Health and Human Development (NICHD), a civilian agency, to Applied Stemcell, Inc. for the generation of point mutation induced pluripotent stem (iPS) or embryonic stem (ES) cell lines using CRISPR/Cas9 gene editing technology. The work is to be performed in Bethesda, MD and has a completion date of March 31, 2022. Applied Stemcell, Inc. is a minority-owned, woman-owned small business that provides...